 Cystic Fibrosis
"Cystic Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Descriptor ID |
D003550
|
| MeSH Number(s) |
C06.689.202 C08.381.187 C16.320.190 C16.614.213
|
| Concept/Terms |
Pancreatic Cystic Fibrosis- Pancreatic Cystic Fibrosis
- Cystic Fibrosis, Pancreatic
- Fibrocystic Disease of Pancreas
- Pancreas Fibrocystic Disease
- Pancreas Fibrocystic Diseases
- Cystic Fibrosis of Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis".
This graph shows the total number of publications written about "Cystic Fibrosis" by people in this website by year, and whether "Cystic Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 | | 1996 | 4 | 1 | 5 | | 1997 | 3 | 1 | 4 | | 1998 | 4 | 1 | 5 | | 1999 | 3 | 1 | 4 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 2 | 7 | | 2002 | 12 | 0 | 12 | | 2003 | 8 | 0 | 8 | | 2004 | 13 | 0 | 13 | | 2005 | 15 | 4 | 19 | | 2006 | 12 | 3 | 15 | | 2007 | 21 | 2 | 23 | | 2008 | 13 | 3 | 16 | | 2009 | 18 | 1 | 19 | | 2010 | 21 | 3 | 24 | | 2011 | 15 | 1 | 16 | | 2012 | 19 | 1 | 20 | | 2013 | 3 | 2 | 5 | | 2014 | 21 | 2 | 23 | | 2015 | 26 | 0 | 26 | | 2016 | 29 | 1 | 30 | | 2017 | 24 | 1 | 25 | | 2018 | 27 | 4 | 31 | | 2019 | 37 | 2 | 39 | | 2020 | 38 | 1 | 39 | | 2021 | 51 | 2 | 53 | | 2022 | 51 | 0 | 51 | | 2023 | 58 | 0 | 58 | | 2024 | 33 | 3 | 36 | | 2025 | 12 | 0 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis" by people in Profiles.
-
Jathal I, Stransky OM, Wright CE, Prangley A, Tangpricha V, Jain R, Taylor-Cousar JL, Hughan KS, Ladores-Barrett S, West NE, Sawicki GS, Kazmerski TM. Fertility and family-building experiences and perspectives of males with cystic fibrosis. Reprod Biol Endocrinol. 2025 Jun 02; 23(1):85.
-
Auth R, Rhoads S, Blundin M, Dziok A, Caddick-Dowty S, Banerjee D. Improving Inpatient Cystic Fibrosis Exacerbation Care: A Resident Physician Training Approach. R I Med J (2013). 2025 Apr 01; 108(4):26-31.
-
Gross JE, Jones MC, Buige A, Prevots DR, Kasperbauer S. Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2025 Jan-Dec; 19:17534666251323181.
-
Calhoun KM, Armantrout E, Poch K, Caceres S, Lovell VK, Jones M, Malcolm KC, Vestal B, Wheeler E, Rysavy N, Manzer J, Aboellail I, Chatterjee D, Nick JA. Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis. PLoS One. 2025; 20(3):e0309191.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
-
Everhart RS, Saavedra MT, Ford CR, Gibson SL, Reid F, Muther EF, Duncan CL, Cravens R, Green A, Riekert KA. Mental health and adherence in CF: Self-efficacy and perceived barriers as mediators. J Cyst Fibros. 2025 Mar; 24(2):334-340.
-
Godfrey EM, Magaret A, Roe A, Taylor-Cousar JL, Walker P, Langfelder-Schwind E, Kazmerski TM, Jain R, Mody SK, Uluer A, West NE, Bray LA, Hsu C, Fiastro A, Stukovsky KDH, Hadjiliadis D, Solomon GM, Ladores-Barrett S. Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers. J Cyst Fibros. 2025 May; 24(3):491-497.
-
Wisniewski BL, Shrestha M, Bojja D, Shrestha CL, Lee CS, Ozuna H, Rayner RE, Bai S, Cormet-Boyaka E, Reynolds SD, Kopp BT. Secondhand vape exposure regulation of CFTR and immune function in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol. 2025 Mar 01; 328(3):L324-L333.
-
Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros. 2025 Mar; 24(2):246-254.
-
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025 Mar; 13(3):256-271.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|